Dow Jones

39,869.38

0.00%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

LVTX

LAVA Therapeutics NV (LVTX)

LAVA Therapeutics NV

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:LVTX

1 2 3 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
25/01/2024	07:07	Dow Jones News	Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda	NASDAQ:LVTX	LAVA Therapeutics NV
16/11/2023	15:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LVTX	LAVA Therapeutics NV
06/09/2023	06:11	GlobeNewswire Inc.	LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:LVTX	LAVA Therapeutics NV
22/08/2023	06:00	GlobeNewswire Inc.	LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results	NASDAQ:LVTX	LAVA Therapeutics NV
14/08/2023	06:00	GlobeNewswire Inc.	LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference	NASDAQ:LVTX	LAVA Therapeutics NV
15/06/2023	15:51	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:LVTX	LAVA Therapeutics NV
14/06/2023	08:00	GlobeNewswire Inc.	LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway	NASDAQ:LVTX	LAVA Therapeutics NV
08/06/2023	06:00	GlobeNewswire Inc.	LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results	NASDAQ:LVTX	LAVA Therapeutics NV
06/06/2023	05:02	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:LVTX	LAVA Therapeutics NV
05/06/2023	17:31	Edgar (US Regulatory)	Report of Proposed Sale of Securities (144)	NASDAQ:LVTX	LAVA Therapeutics NV
01/06/2023	18:38	Dow Jones News	Stocks to Watch: Lululemon, Lava Therapeutics, Tilly's, Oncorus	NASDAQ:LVTX	LAVA Therapeutics NV
01/06/2023	15:20	GlobeNewswire Inc.	LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development	NASDAQ:LVTX	LAVA Therapeutics NV
01/06/2023	07:09	GlobeNewswire Inc.	LAVA Therapeutics to Participate in the Jefferies Healthcare Conference	NASDAQ:LVTX	LAVA Therapeutics NV
30/05/2023	16:28	GlobeNewswire Inc.	LAVA Announces Annual Meeting of Shareholders	NASDAQ:LVTX	LAVA Therapeutics NV
11/04/2023	06:00	GlobeNewswire Inc.	LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results	NASDAQ:LVTX	LAVA Therapeutics NV
09/03/2023	07:05	GlobeNewswire Inc.	LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors	NASDAQ:LVTX	LAVA Therapeutics NV
16/02/2023	06:00	GlobeNewswire Inc.	LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium	NASDAQ:LVTX	LAVA Therapeutics NV
09/02/2023	06:00	GlobeNewswire Inc.	LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference	NASDAQ:LVTX	LAVA Therapeutics NV
06/02/2023	06:00	GlobeNewswire Inc.	LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer	NASDAQ:LVTX	LAVA Therapeutics NV
23/01/2023	06:00	GlobeNewswire Inc.	LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium	NASDAQ:LVTX	LAVA Therapeutics NV
06/01/2023	12:07	GlobeNewswire Inc.	LAVA Therapeutics Announces Appointment of New Directors to the Board	NASDAQ:LVTX	LAVA Therapeutics NV
03/01/2023	06:00	GlobeNewswire Inc.	LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference	NASDAQ:LVTX	LAVA Therapeutics NV
23/12/2022	15:02	Edgar (US Regulatory)	Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)	NASDAQ:LVTX	LAVA Therapeutics NV
12/12/2022	05:25	TipRanks	H.C. Wainwright Keeps Their Buy Rating on LAVA Therapeutics (LVTX)	NASDAQ:LVTX	LAVA Therapeutics NV
10/12/2022	09:00	GlobeNewswire Inc.	LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition	NASDAQ:LVTX	LAVA Therapeutics NV
16/11/2022	15:05	GlobeNewswire Inc.	LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results	NASDAQ:LVTX	LAVA Therapeutics NV
03/11/2022	15:05	GlobeNewswire Inc.	LAVA Therapeutics to Present at the Jefferies London Healthcare Conference	NASDAQ:LVTX	LAVA Therapeutics NV
03/11/2022	08:00	GlobeNewswire Inc.	LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition	NASDAQ:LVTX	LAVA Therapeutics NV
01/11/2022	06:00	GlobeNewswire Inc.	LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer	NASDAQ:LVTX	LAVA Therapeutics NV
07/10/2022	10:00	GlobeNewswire Inc.	LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting	NASDAQ:LVTX	LAVA Therapeutics NV